Innoviva (INVA) Non-Current Deffered Revenue (2010 - 2017)
Innoviva (INVA) posted Non-Current Deffered Revenue of $1.6 million for Q3 2017, down 12.47% on a QoQ basis from $1.8 million in Q2 2017, and down 36.3% year-over-year from $2.4 million in Q3 2016.
Innoviva (INVA) Non-Current Deffered Revenue (2010 - 2017) Analysis & Trends
Innoviva's Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $1.6 million for Q3 2017.
- Quarterly Non-Current Deffered Revenue fell 36.3% year-over-year to $1.6 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $1.6 million (down 36.3% YoY) and the FY2016 annual result came in at $2.2 million, down 28.56% from the prior year.
- Non-Current Deffered Revenue was $1.6 million for Q3 2017 at Innoviva, down from $1.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $5.7 million in Q1 2013 and bottomed at $13000.0 in Q2 2014.
- A 5-year average of $2.8 million and a median of $2.7 million in 2016 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2014 — Non-Current Deffered Revenue plunged 99.72% — and 2016, when it surged 3133.71%.
- Innoviva's Non-Current Deffered Revenue stood at $5.5 million in 2013, then tumbled by 30.56% to $3.8 million in 2014, then declined by 18.19% to $3.1 million in 2015, then dropped by 28.56% to $2.2 million in 2016, then retreated by 29.95% to $1.6 million in 2017.
- Business Quant data shows INVA's Non-Current Deffered Revenue at $1.6 million in Q3 2017, $1.8 million in Q2 2017, and $2.0 million in Q1 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 1.55 Mn |
| Jun 30, 2017 | 1.77 Mn |
| Mar 31, 2017 | 1.99 Mn |
| Dec 31, 2016 | 2.21 Mn |
| Sep 30, 2016 | 2.44 Mn |
| Jun 30, 2016 | 2.66 Mn |
| Mar 31, 2016 | 2.88 Mn |
| Dec 31, 2015 | 3.10 Mn |
| Sep 30, 2015 | 100,000.00 |
| Jun 30, 2015 | 102,000.00 |
| Mar 31, 2015 | 89,000.00 |
| Dec 31, 2014 | 3.79 Mn |
| Sep 30, 2014 | 4.06 Mn |
| Jun 30, 2014 | 13,000.00 |
| Mar 31, 2014 | 4.89 Mn |
| Dec 31, 2013 | 5.46 Mn |
| Sep 30, 2013 | 5.15 Mn |
| Jun 30, 2013 | 4.70 Mn |
| Mar 31, 2013 | 5.67 Mn |
| Dec 31, 2012 | 5.07 Mn |